covid-19 cytotoxic t lymphocytes
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 15, 2021 (NCT04765449)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, passive
SARS-CoV-2 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04765449 | Phase 1 | Sep 15, 2021 | Tevogen, Thomas Jefferson University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tevogen | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Thomas Jefferson University | Academic/Hospital | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1